How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

419 results for

Fragile X-Associated Tremor-Ataxia Syndrome

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Ubiquitin-Positive Intranuclear Inclusions in Neuronal and Glial Cells in a Mouse Model of the Fragile-X Premutation (PubMed)

Ubiquitin-Positive Intranuclear Inclusions in Neuronal and Glial Cells in a Mouse Model of the Fragile-X Premutation Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder caused by CGG trinucleotide repeat expansions in the fragile X mental retardation 1 (FMR1) gene. The neuropathological hallmark of the disease is the presence of ubiquitin-positive intranuclear inclusions in neurons and in astrocytes. Ubiquitin-positive intranuclear inclusions have

Full Text available with Trip Pro

2010 Brain research

122. Lifetime prevalence of mood and anxiety disorders in fragile x premutation carriers. (PubMed)

Lifetime prevalence of mood and anxiety disorders in fragile x premutation carriers. The authors studied the lifetime prevalence of DSM-IV-TR psychiatric disorders in a population of adults with the fragile X premutation.The Structured Clinical Interview for DSM-IV was conducted, from 2007-2008, in 85 individuals with the fragile X premutation, 47 with the fragile X-associated tremor/ataxia syndrome (FXTAS; 33 male, 14 female; mean age = 66 years) and 38 without FXTAS (16 male, 22 female; mean (...) of the fragile X premutation had a notably high lifetime risk of mood and anxiety disorders. Mood and anxiety disorders may be part of the clinical phenotype of the fragile X premutation conditions, especially in carriers with FXTAS. Clinicians encountering these patients are advised to consider FXTAS as a neuropsychiatric syndrome as well as a neurologic disorder.© Copyright 2011 Physicians Postgraduate Press, Inc.

Full Text available with Trip Pro

2010 Journal of Clinical Psychiatry

123. Hyperammonemia-Hyperornithinemia-Homocitrullinemia Syndrome (Diagnosis)

. 1997 Sep. 131(3):440-3. . Media Gallery Important products and enzymes in ornithine metabolism (see text for pathway detail). Enzymes and transporters are highlighted in italics. of 1 Tables Contributor Information and Disclosures Author Richard E Frye, MD, PhD Professor of Child Health, University of Arizona College of Medicine at Phoenix; Chief of Neurodevelopmental Disorders, Director of Autism and Down Syndrome and Fragile X Programs, Barrow Neurological Institute at Phoenix Children's Hospital (...) at presentation and long-term prognosis widely vary among affected individuals. Growth and developmental delays, learning disabilities (especially speech delay), and periodic confusion and ataxia are typical presenting symptoms. In this syndrome, a defect in the transport of ornithine into the mitochondrial matrix significantly inhibits the urea cycle, thereby impeding nitrogen disposal. Early detection and treatment may lead to favorable outcome. Next: Pathophysiology The urea cycle maintains

2014 eMedicine Pediatrics

124. Hyperammonemia-Hyperornithinemia-Homocitrullinemia Syndrome (Overview)

. 1997 Sep. 131(3):440-3. . Media Gallery Important products and enzymes in ornithine metabolism (see text for pathway detail). Enzymes and transporters are highlighted in italics. of 1 Tables Contributor Information and Disclosures Author Richard E Frye, MD, PhD Professor of Child Health, University of Arizona College of Medicine at Phoenix; Chief of Neurodevelopmental Disorders, Director of Autism and Down Syndrome and Fragile X Programs, Barrow Neurological Institute at Phoenix Children's Hospital (...) at presentation and long-term prognosis widely vary among affected individuals. Growth and developmental delays, learning disabilities (especially speech delay), and periodic confusion and ataxia are typical presenting symptoms. In this syndrome, a defect in the transport of ornithine into the mitochondrial matrix significantly inhibits the urea cycle, thereby impeding nitrogen disposal. Early detection and treatment may lead to favorable outcome. Next: Pathophysiology The urea cycle maintains

2014 eMedicine Pediatrics

125. Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders (PubMed)

in a growing number of diseases, including spinocerebellar ataxia type 8 (SCA8), myotonic dystrophy type 1 (DM1), Fragile-X tremor ataxia syndrome (FXTAS), and C9ORF72 amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD). Copyright © 2014 Elsevier Ltd. All rights reserved. (...) Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders Microsatellite-expansion diseases are a class of neurological and neuromuscular disorders caused by the expansion of short stretches of repetitive DNA (e.g. GGGGCC, CAG, CTG …) within the human genome. Since their discovery 20 years ago, research into how microsatellites expansions cause disease has been examined using the model that these genes are expressed in one direction and that expansion

Full Text available with Trip Pro

2014 Current opinion in genetics & development

126. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. (PubMed)

Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Within the past few years, there has been a significant change in identifying and characterizing the FMR1 premutation associated phenotypes. The premutation has been associated with elevated FMR1 mRNA levels and slight to moderate reductions in FMRP levels. Furthermore, it has been established that approximately 20% of female premutation carriers present primary ovarian insufficiency (POI) and that fragile X (...) -associated tremor/ataxia syndrome (FXTAS) occurs in one-third of all male premutation carriers older than 50 years. Besides POI and FXTAS, new disorders have recently been described among individuals (especially females) with the FMR1 premutation. Those pathologies include thyroid disease, hypertension, seizures, peripheral neuropathy, and fibromyalgia. However there are few reports related to FXTAS penetrance among female premutation carriers or regarding these disorders recently associated to the FMR1

Full Text available with Trip Pro

2009 European Journal of Human Genetics

127. Advances in the Treatment of Fragile X Syndrome. (PubMed)

Advances in the Treatment of Fragile X Syndrome. The FMR1 mutations can cause a variety of disabilities, including cognitive deficits, attention-deficit/hyperactivity disorder, autism, and other socioemotional problems, in individuals with the full mutation form (fragile X syndrome) and distinct difficulties, including primary ovarian insufficiency, neuropathy and the fragile X-associated tremor/ataxia syndrome, in some older premutation carriers. Therefore, multigenerational family involvement (...) is commonly encountered when a proband is identified with a FMR1 mutation. Studies of metabotropic glutamate receptor 5 pathway antagonists in animal models of fragile X syndrome have demonstrated benefits in reducing seizures, improving behavior, and enhancing cognition. Trials of metabotropic glutamate receptor 5 antagonists are beginning with individuals with fragile X syndrome. Targeted treatments, medical and behavioral interventions, genetic counseling, and family supports are reviewed here.

Full Text available with Trip Pro

2009 Pediatrics

128. CGG-repeat expansion in FMR1 is not associated with amyotrophic lateral sclerosis. (PubMed)

known to cause spinocerebellar ataxia type 2, has been identified as a major risk factor for sporadic ALS. Intermediate repeat expansions in the fragile X mental retardation 1 (FMR1) gene (55-200 repeats) are known to cause fragile X-associated premature ovarian insufficiency [(FX)POI; female carriers] or fragile X-associated tremor/ataxia syndrome (FXTAS; male carriers) by CGG-mediated RNA toxicity. The present investigation involves screening FMR1 repeat length in 742 sporadic ALS patients and 792 (...) CGG-repeat expansion in FMR1 is not associated with amyotrophic lateral sclerosis. Recently, repeat expansions in several genes have been shown to cause or be associated with amyotrophic lateral sclerosis (ALS). It has been demonstrated that an intronic hexanucleotide repeat expansion in C9ORF72 is a major cause of both familial (approximately 40%) and sporadic (approximately 5%) ALS, as well as frontotemporal dementia (FTD). In addition, a CAG-repeat expansion in exon 1 of ATXN2, otherwise

2012 Neurobiology of Aging

129. Cerebral palsy in adults

, consider referring them to a specialised centre with experience in providing deep brain stimulation. See also NICE interventional procedures guidance on deep brain stimulation for tremor and dystonia (excluding Parkinson's diseas). Cerebral palsy in adults (NG119) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 19 of 64T o find out why the committee made the recommendations on neurosurgical treatments to reduce (...) to be moved, for example, hoisting history of falls low BMI history of low-impact fractures other medical factors, for example steroid use, that may adversely affect bone health. Cerebral palsy in adults (NG119) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 20 of 64For more information about assessment of fracture risk, see NICE's guideline on osteoporosis: assessing the risk of fragility fracture. 1.4.4 Consider a dual

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

130. Neuroleptic Malignant Syndrome

Overview of Heat Illness Withdrawal from which of the following substances is most likely to increase a patient’s heat input? Alcohol Cannabis Cocaine Phencyclidine NEWS & VIDEOS Fractures Have Long-Term Impact on Quality of Life for Older Adults TUESDAY, Feb. 12, 2019 (HealthDay News) -- Incident fragility fractures are associated with long-term impacts on health-related quality of life (HRQOL) in older people, according to a study... 3D Model Musculoskeletal Connective Tissues Video How to Do (...) Neuroleptic Malignant Syndrome Neuroleptic Malignant Syndrome - Injuries; Poisoning - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge

2013 Merck Manual (19th Edition)

131. Ehlers-Danlos Syndrome

, classic, and hypermobility types. Ehlers-Danlos Syndrome ST MARYS HOSPITAL MEDICAL SCHOOL/SCIENCE PHOTO LIBRARY Bleeding tendency is rare, although the vascular type is characterized by vascular rupture and bruising. Subcutaneous calcified spherules may be palpated or seen on x-rays. Complications of Ehlers-Danlos syndrome Minor trauma may cause wide gaping wounds but little bleeding; surgical wound closure may be difficult because sutures tend to tear out of the fragile tissue. Surgical complications (...) ) Syndromes Cerebral palsy syndromes are categorized based on which parts of the CNS are malformed or damaged. Spastic syndromes occur in > 70% of cases. Which of the following is a typical symptom in spastic cerebral palsy syndromes? Athetoid movements Intention tremor A scissors gait A wide-based gait NEWS & VIDEOS February 2019 Briefing - Psychiatry Here are what the editors at HealthDay consider to be the most important developments in Psychiatry for February 2019. This roundup includes the latest

2013 Merck Manual (19th Edition)

132. Progressive Spatial Processing Deficits in a Mouse Model of the Fragile X Premutation (PubMed)

Progressive Spatial Processing Deficits in a Mouse Model of the Fragile X Premutation Fragile X associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder that is the result of a CGG trinucleotide repeat expansion in the range of 55-200 in the 5' UTR of the FMR1 gene. To better understand the progression of this disorder, a knock-in (CGG KI) mouse was developed by substituting the mouse CGG8 trinucleotide repeat with an expanded CGG98 repeat from human origin. It has been shown

Full Text available with Trip Pro

2009 Behavioral neuroscience

133. Appropriate Use Criteria: Imaging of the Brain

, diagnoses, or imaging modalities not specifically addressed are considered not medically necessary. It is recognized that imaging often detects abnormalities unrelated to the condition being evaluated. Such findings must be considered within the context of the clinical situation when determining whether additional imaging is required. Congenital and Developmental Conditions Ataxia, congenital or hereditary Includes ataxia-telangiectasia, fragile X syndrome, and congenital anomalies of the posterior (...) postures. The diagnosis is clinical and specialist referral is recommended. Features of primary dystonia include the following: absence of associated neurological signs or symptoms other than tremor; absence of additional motor abnormalities (weakness, spasticity, etc.); early onset ( 20, respectively. 119 In a 2 single-center retrospective studies, MRI changed management in 16%-21.6% of patients with central vertigo. 120,121 CT imaging may also be performed, although MRI is more sensitive than CT

2019 AIM Specialty Health

134. Plitidepsin (Aplidin) - Multiple Myeloma

%. Despite progress in its current treatment and management, MM remains incurable. Although ASCT has extended survival in newly diagnosed MM, practically all patients eventually relapse (3) (6). In addition, approximately two thirds of newly diagnosed patients aged > 65 years are ineligible for this treatment. The treatment option for the majority of the MM population, i.e., the more fragile and elderly patients, is associated with low response rate and short survival. Assessment report EMA/249101/2018 (...) Response Vss Volume of Distribution at Steady State WFI Water for injections XRPD X-ray powder diffraction y.o. Years Old Assessment report EMA/249101/2018 Page 11/156 1. Background information on the procedure 1.1. Submission of the dossier The applicant Pharma Mar, S.A. submitted on 21 September 2016 an application for marketing authorisation to the European Medicines Agency (EMA) for Aplidin, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC

2018 European Medicines Agency - EPARs

135. Dolutegravir sodium rilpivirine hydrochloride (Juluca) - HIV Infections

was performed after 56 subjects had been dosed to evaluate the appropriateness of the assumed PK parameter variability and associated sample size. Based on the higher RPV CVw observed (32.9% for C max ), 32 additional subjects were recruited. Results The pharmacokinetic variables of DTG and RPV for both treatments (A: FDC tablet formulation DTG/RPV 50 mg/25 mg; B: DTG 50 mg plus RPV 25 mg) are shown in Table 8 and Table 9 respectively. DTG and RPV systemic exposure in terms of C max , AUC 0-t and AUC 0-8 (...) . The pharmacokinetic results are shown in Table 6 and 7. Table 6. Summary of dolutegravir pharmacokinetic parameters and statistical treatment comparisons following repeat dose administration of dolutegravir with and without rilpivirine 1. Geometric mean [95% CI] (Between subject variability CVb%) 2. GLS Mean Ratio [90% CI] 3. Median (range) Treatments: DTG = DTG 50 mg QD x 5 days DTG + RPV = DTG 50 mg QD + RPV 25 mg QD x 5 days Assessment report EMA/243517/2018 Page 45/109 Table 7. Summary of rilpivirine

2018 European Medicines Agency - EPARs

136. CRACKCast E144 – High Altitude Medicine

descend immediately. Dyspnea at rest is an early symptom of HAPE . More advance findings of HAPE include marked rest tachypnea, cough productive of frothy sputum, and altered mentation. Immediate treatment with oxygen and descent are recommended. Altered consciousness and cerebellar ataxia are early signs of HACE . F ailure to initiate immediate treatment with oxygen, descent, and dexamethasone can result in permanent disability or death. AMS may be prevented by using acetazolamide or dexamethasone (...) less common < 1% with rapid ascents > 4300 meters. High-altitude pulmonary edema (HAPE) is the primary lung syndrome. HAPE is the leading cause of death from altitude illness . It’s incidence ranges from 0.01% to 15% with rapid ascents (as cited in Rosen’s from Auerbach 2012) The pathophysiologic effects of high altitude begin when the oxygen saturation of the arterial blood begins to fall below the 90% level. The sigmoidal shape of the oxyhemoglobin dissociation curve prevents a significant fall

2018 CandiEM

137. CRACKCast E143 – Diving Injuries and Dysbarism

spaces in the body (lungs, bowel, sinuses, middle ear). These fragile structures (just like any other hollow tube (tire, balloon)) don’t do well when they are overfilled! Boyle’s Law : P1V1 = P2V2 (at a constant temp) The pressure and volume of a gas are inversely proportional to each other. …the volume of a gas (air) will decrease as the pressure (due to depth) increases. **this also applies to changes that occur in gas supplies** We care because as dives deeper (more pressure), the gas bubble (...) volume will decrease. The greatest change happens in the first 33 ft (100% → 50% volume change) Low pressure = high volume; high pressure = low volume. Charles’ Law: V1/T1 = V2/T2 Addresses the effect of temperature on gases: “at a constant pressure, the volume of a gas is directly proportional to the change in absolute temperature. Therefore, with head the volume of a gas will increase. General Gas Law: P1 x V1/T1 = P2 x V2/T2 This law combines charles’ boyle’s gas laws. It relates pressure, volume

2018 CandiEM

138. Standards and guidelines for clinical genetics laboratories - cytogenetics

. In addition, complete high resolution chromosome analysis should include detailed evaluation of all regions on all chromosome pairs at a level of resolution above the 650-band stage (resolution at the 850 level is 12 recommended) [see also E5.1.2]. E5.4 Peripheral Blood (Stimulated Lymphocytes): Heritable Fragile Sites (Including Fragile X) This section initially provided guidelines for the evaluation of patients for fragile X syndrome using the cytogenetic expression of the Xq27.3 (FRAXA) fragile site (...) . Such chromosome testing has been replaced by molecular genetic DNA evaluation of the FMR1 locus, and specific College recommendations have been published to cover such testing (see Section FX, "Technical Standards and Guidelines for Fragile X") [Maddalena et al., 2001; Monaghan, Lyon and Spector, 2013]. For the most part, testing/culturing for fragile sites is no longer performed in the Cytogenetics Laboratory. However, individuals performing chromosome analyses should be aware of their occurrence (e.g. fra

2018 American College of Medical Genetics and Genomics

139. Assessment, diagnosis and interventions for autism spectrum disorders

is not causal 3 Non-analytic studies, eg case reports, case series 4 Expert opinion RECOMMENDATIONS Some recommendations can be made with more certainty than others. The wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made (the ‘strength’ of the recommendation). The ‘strength’ of a recommendation takes into account the quality (level) of the evidence. Although higher-quality evidence is more likely to be associated with strong recommendations than (...) and diagnosis 6 2.3 Non-pharmacological interventions for children 6 2.4 Non-pharmacological interventions for adults 6 3 Definitions and concepts 7 3.1 Definitions 7 3.2 Diagnostic criteria 7 4 Recognition, assessment and diagnosis 8 4.1 Recognition in primary care 8 4.2 Methods of assessment 12 4.3 Individual profiling 15 4.4 Conditions associated with ASD 16 4.5 Biomedical investigations 17 4.6 Prognostic indicators in childhood 19 5 Principles of intervention 20 6 Non-pharmacological interventions

2016 SIGN

140. Acute lymphoblastic leukemia

and inherited diseases with excessive chromosomal fragility such as Fanconi’s anemia, Bloom’s syndrome and ataxia-telangiectasia have a higher risk of developing ALL (Jabbour, et al 2005). However, in the majority of ALL patients no gross chromosomal alteration is noted suggesting that additional submicroscopic genetic alterations likely contribute to leukaemogenesis (Inaba, et al 2013). Genome-wide association studies of childhood ALL (Inaba, et al 2013) have noted common allelic variants in IKZF1, ARID5B (...) ) relatively specific. t(12;21)(p13;q22); TEL-AML1 (ETV6- RUNX1) Rare in adulthood CD19+ve, CD10+ve, CD34 +ve (commonly) May have near or complete absence of CD9/CD220/CD66c Myleoid antigens (CD13) frequently expressed. ?necessary but sufficient for leukemic translocation? Hyperdiploidy >50 and usually 30 x 10 9 /L for Pre-B ALL or >100 x 10 9 /L for T-ALL) was associated with inferior RFS and OS (Storring, et al 2009). The role of age and WBC was questiond by the Southwest Oncology Group (SWOG) who noted

2016 CPG Infobase

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>